Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension-Reference-Cited by-同舟云学术

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Published:2022-05-19 Issue:8 Volume:24 Page:1553-1564
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Wilding John P. H.¹^ORCID,Batterham Rachel L.²³⁴^ORCID,Davies Melanie⁵⁶^ORCID,Van Gaal Luc F.⁷,Kandler Kristian⁸^ORCID,Konakli Katerina⁸^ORCID,Lingvay Ildiko⁹^ORCID,McGowan Barbara M.¹⁰,Oral Tugce Kalayci⁸^ORCID,Rosenstock Julio¹¹^ORCID,Wadden Thomas A.¹²^ORCID,Wharton Sean¹³^ORCID,Yokote Koutaro¹⁴,Kushner Robert F.¹⁵^ORCID,

Affiliation:

1. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences University of Liverpool Liverpool UK

2. University College London Centre for Obesity Research, Division of Medicine University College London London UK

3. National Institute of Health Research UCLH Biomedical Research Centre London UK

4. Centre for Weight Management and Metabolic Surgery, University College London Hospital London UK

5. Diabetes Research Centre University of Leicester Leicester UK

6. NIHR Leicester Biomedical Research Centre Leicester UK

7. Department of Endocrinology, Diabetology and Metabolism Antwerp University Hospital, University of Antwerp Antwerp Belgium

8. Novo Nordisk A/S Søborg Denmark

9. Departments of Internal Medicine/Endocrinology and Department of Population and Data Sciences University of Texas Southwestern Medical Center Dallas Texas USA

10. Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Foundation Trust London UK

11. Dallas Diabetes Research Center at Medical City Dallas Texas USA

12. Department of Psychiatry, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

13. York University, McMaster University and Wharton Weight Management Clinic Toronto Ontario Canada

14. Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University and Department of Diabetes, Metabolism and Endocrinology Chiba University Hospital Chiba Japan

15. Division of Endocrinology, Feinberg School of Medicine Northwestern University Chicago Illinois USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14725

Reference25 articles.

1. Progress and challenges in anti-obesity pharmacotherapy

2. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity

3. World Health Organization. Obesity and overweight.2020.https://www.who.int/news‐room/fact‐sheets/detail/obesity‐and‐overweight. Accessed January 11 2022.

4. European Guidelines for Obesity Management in Adults

5. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial;The Lancet Diabetes & Endocrinology;2024-02

2. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism;Molecular Metabolism;2024-02

3. Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study;International Journal of Obesity;2024-02-01

4. Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years;Journal of the American College of Cardiology;2024-02

5. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective;International Journal of Obesity;2024-01-31